Transparency and Trust
Ipsen acknowledges that transparency is necessary to build trust with patients, policy-makers, healthcare professionals (HCPs), healthcare organisations (HCOs) and citizens.
Ipsen commits to meet in a timely manner the growing and legitimate expectations related to healthcare matters of Society. For this purpose, Ipsen seeks to enhance the understanding on the way our sector operates.
Ipsen conforms to the highest ethical standards, in compliance with the ruling laws, regulations and industry codes.
As such, Ipsen discloses information concerning:
- The transfer of values to HCPs/HCOs
- Clinical trials
- Scientific publications
- Interactions with policy-makers
To build relations trustworthy relations with patients, stakeholders and general public, Ipsen is guided by a policy of transparency in every aspect of its interactions with healthcare professionals and organizations. We are committed to being compliant with the ethical rules applicable to the pharmaceutical industry.
THE RELATIONSHIP BETWEEN INDUSTRY, HEALTHCARE PROFESSIONALS (HCPs) AND HEALTHCARE ORGANIZATIONS (HCOs)
Interactions between industries and health professionals are a positive driver for the development of patient treatment and value of research advancements in patient care and progression of innovative medicines.
Collaboration between industry and HCPs benefits patients. It is a relationship that has delivered numerous innovative medicines, improved the management of many diseases, and reduced their impact on our lives.
Collaborative activities include conducting clinical research, sharing best clinical practice, and exchanging information on how new medicines fit into the treatment pathway.
Opportunities for exchange include advisory boards, chairing and speaking at meetings, consultancy services or attendance at medical education events such as congresses.
To maintain trust, society has growing expectations for transparency, particularly in healthcare. We want to meet those expectations. We are keen to work with the HCP community and professional organisations to ensure this vital relationship is fully understood by patients, patient advocacy groups, the media and the general public.
The relationship between the pharmaceutical industry and HCPs is extensively regulated in the interests of patients and the general population.
Requirements for all aspects of the interaction between the pharmaceutical industry and HCPs are clearly defined, and serve to protect HCPs’ clinical independence, expertise and decision making.
These requirements continue to evolve over time as the nature of healthcare, medical science and societal expectations change.
All interactions with European HCPs are governed by EU Directive 2001/83/EC on the Community Code relating to medicinal products for human use, the EFPIA HCP Code, applicable EFPIA Member Associations’ national codes and any other applicable (local) internal policies, procedures and laws.
Bringing optimal transparency to this already well-regulated and vital relationship aims to build a better understanding of the pharmaceutical industry/HCP and HCO collaboration.
In Europe, the European Federation of Pharmaceutical Industries and Associations (EFPIA) decreed the EFPIA Disclosure Code (June 2013), which requires the public disclosure of payments to HCPs and HCOs, starting in 2016 (for payments made in 2015).
In the USA, commercial interactions with HCPs are governed by the PhRMA Code on Interactions with Healthcare Professionals (2008). From a transparency perspective, the Patient Protection and Affordable Care Act (2010) (“Sunshine Act”) requires manufacturers to collect and track all financial relationships with physicians and teaching hospitals and to report these data to the Centers for Medicare and Medicaid Services (CMS).
The disclosures include transfers of value made for activities such as research and educational grants to HCOs as well as transfers of value to HCPs such as speaker fees, consultancy activities and participation in advisory boards.
The pharmaceutical industry and the healthcare community at large share the common goal of ensuring patients receive optimal care. Interactions between the medical community and the pharmaceutical industry are essential for the best patient outcomes.
Increasing transparency through the individual disclosure of transfers of value is good for all stakeholders, including HCPs, because it increases understanding of this important collaboration.
The public disclosure of transfers of value marks a significant development in the relationship between the pharmaceutical industry and HCPs.
Ipsen is committed to working with all stakeholders in healthcare to ensure the value of these relationships and the benefits of greater transparency are understood.
Ipsen Senior Vice President,
Chief Ethics and Compliance Officer
Ipsen is dedicated to promoting transparency by providing a clear view, to all its stakeholders, of its interactions with healthcare professionals and healthcare organizations.
We deeply believe this is the right way to build a collaborative relationship with our healthcare professional partners, based on integrity and information sharing.”
Please follow the links to the countries to find the information about local Transparency rules and reports:
- Bulgaria No transfer of value in 2016
- Cyprus No Transfer of value in 2016
- Czech Republic
- Iceland No Transfer of value in 2016
- The Netherlands
Publication of transfers of value to Recipients aims at reporting the values (monetary or in-kind) to HCPs/HCOs our company is collaborating/has relationships with, following the objectives and provisions included in the applicable codes. Individual disclosures have been consented to by individual Recipients – such consent has been given to allow complying with the applicable codes that our company signed off to.
These publications do not grant a general permission for those accessing our website or the national platforms to undertake additional processing of the healthcare professionals’ data.
For a good understanding of the reporting included in our disclosures as published on this website, we refer to the Methodological Note that clarifies the meaning and content of the transfers of value reported.